Table 2.

Clinical characteristics of CML patients

Patient Age/Sex at BMT Time From dx to BMT (y) Treatment Pre-BMT BMT Conditioning RegimenPre T-Cell Depletion #CD3+ Cells/kg #CD3+ Cells/kg Infused at BMT IL-2 After BMT GVHD After BMT (grade)Time From BMT to Cytogenetic Relapse (mo)
1  47M 3  Hy  Busulfan/CTX  2.5 × 107 0.6 × 106 Yes  0  12  
2  38F  2 Hy  splenic XRT  1.9 × 107 0.8 × 106 Yes  0  6 
    CTX/TBI  
3  52F  4  IFN  splenic XRT 1.7 × 107 1.4 × 106 No  0  36  
    CTX/TBI  
4  57F  0.4  Hy CTX/TBI  2.0 × 107 1.1 × 106 Yes  1 (skin)  12  
5  49F  0.5  Hy  CTX/TBI 2.2 × 107 1.2 × 106 Yes 0  7  
6  43M  1  Hy  CTX/TBI 1.6 × 107 1.1 × 106 Yes 0  36  
7  41F  1  Hy  CTX/TBI 2.5 × 107 0.2 × 106 Yes 1 (skin)  
8  31M  1  Hy  TLI/CTX/TBI 2.0 × 107 0.3 × 106 Yes 0  
9  33F  1  Hy  CTX/TBI 2.3 × 107 1.0 × 106 Yes 0  
10  46M  1  IFN  splenic XRT 2.0 × 107 0.1 × 106 Yes 0  
11  27F  0.6  Hy  CTX/TBI 3.8 × 107 1.5 × 106 No  0 
Patient Age/Sex at BMT Time From dx to BMT (y) Treatment Pre-BMT BMT Conditioning RegimenPre T-Cell Depletion #CD3+ Cells/kg #CD3+ Cells/kg Infused at BMT IL-2 After BMT GVHD After BMT (grade)Time From BMT to Cytogenetic Relapse (mo)
1  47M 3  Hy  Busulfan/CTX  2.5 × 107 0.6 × 106 Yes  0  12  
2  38F  2 Hy  splenic XRT  1.9 × 107 0.8 × 106 Yes  0  6 
    CTX/TBI  
3  52F  4  IFN  splenic XRT 1.7 × 107 1.4 × 106 No  0  36  
    CTX/TBI  
4  57F  0.4  Hy CTX/TBI  2.0 × 107 1.1 × 106 Yes  1 (skin)  12  
5  49F  0.5  Hy  CTX/TBI 2.2 × 107 1.2 × 106 Yes 0  7  
6  43M  1  Hy  CTX/TBI 1.6 × 107 1.1 × 106 Yes 0  36  
7  41F  1  Hy  CTX/TBI 2.5 × 107 0.2 × 106 Yes 1 (skin)  
8  31M  1  Hy  TLI/CTX/TBI 2.0 × 107 0.3 × 106 Yes 0  
9  33F  1  Hy  CTX/TBI 2.3 × 107 1.0 × 106 Yes 0  
10  46M  1  IFN  splenic XRT 2.0 × 107 0.1 × 106 Yes 0  
11  27F  0.6  Hy  CTX/TBI 3.8 × 107 1.5 × 106 No  0 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal